Understand · Treat · Recover

Acute Myeloid Leukemia (AML)

AML is a fast-growing cancer of immature myeloid cells. Prompt assessment is important, but the safest treatment depends on its biology and the person’s health.

For patients and families. This education does not replace an individual treatment plan. Do not start, stop or change medicines without the treating team.

Chapter 4 of 20 · B · Leukemia

How AML presents and is confirmed

Fatigue, infections, bruising or bleeding can develop as normal marrow production falls. The white-cell count may be high, normal or low. Evaluation uses blood counts, a smear, usually bone marrow sampling, and flow cytometry to identify abnormal cells. Kidney function, electrolytes, clotting tests and infection assessment help identify immediate risks. Very high counts with breathing or neurological symptoms can be an emergency.

Genes and chromosomes change the plan

Cytogenetics looks at chromosomes; FISH looks for selected changes; molecular testing searches for gene abnormalities. Findings such as FLT3, NPM1, IDH1/2 and particular chromosome rearrangements can affect treatment and risk assessment. Modern WHO and ICC systems combine these findings with cell appearance and clinical history; their exact diagnostic thresholds differ. Do not interpret AML solely from one blast percentage. Ask which classification and risk system the report uses, and whether an inherited predisposition is suspected.

APL requires an especially urgent pathway

Acute promyelocytic leukemia (APL) is a distinct AML subtype, commonly with PML::RARA. It can cause dangerous clotting and bleeding abnormalities. Suspected APL needs immediate specialist hospital management without waiting for all routine tests. Treatment is often based on all-trans retinoic acid and arsenic trioxide, with other treatment according to risk. It has strong cure prospects with appropriate care, but early complications can be life-threatening. This is not a home-treatment situation.

Intensive and lower-intensity treatment

For suitable patients, induction chemotherapy aims to achieve remission, followed by consolidation to reduce relapse. Targeted medicines may be added when a relevant abnormality is present. For people unlikely to tolerate intensive treatment, options can include a hypomethylating medicine such as azacitidine with venetoclax, or other disease-appropriate approaches. “Lower intensity” does not mean low risk: prolonged low blood counts, infections and tumor lysis still require close monitoring. Age alone is not the decision; organ function, frailty, goals and treatment support matter.

Transplant, MRD and relapse

Measurable residual disease (MRD) tests look below the level visible by routine microscopy. Response, genetic risk and transplant risk help decide whether an allogeneic stem cell transplant is appropriate in remission. It is not necessary for every AML patient. Relapse prompts renewed testing because the leukemia may have changed. Salvage treatment, mutation-directed drugs, clinical trials or transplant may be considered; symptom-focused care remains available at every stage.

Planning care

Ask which tests are urgent and which can follow, where transfusions and emergency admissions will occur, and how costs may change during infections or prolonged count recovery. Arrange access to a 24-hour hematology service. Fertility discussion should happen early when feasible, without delaying emergency stabilization. The outlook varies greatly by subtype, response and fitness; an overall AML survival figure is not a personal prediction.

Take-home message

Confirm the subtype, stabilize urgent complications and use biology plus fitness to plan treatment.

Common questions

Is all AML treated the same way?

No. APL, mutation-defined disease, prior treatment-related disease and different fitness levels can require very different approaches.

Does remission mean treatment is over?

Usually not. Post-remission treatment or maintenance in selected settings may be needed to reduce recurrence risk.

Sources and further reading

Cancer Aware supports patients and families worldwide. Treatment availability, approvals and care pathways vary by country; discuss local options with your healthcare team.